DAWN

Day One Biopharmaceuticals, Inc. is a biotechnology company operating in the healthcare sector. With a market capitalization of $877.88 million and revenue of $133.67 million (TTM), it has a relatively small scale compared to other companies in its industry. Day One Biopharmaceuticals employs 184 individuals. The company's financial health is marked by significant losses, with a net income of -$151,758,000 (TTM) and an EBITDA of -$162,410,000. This results in negative profitability metrics, including an operating margin of -60.9% and a profit margin of -113.5%. The company's returns on equity and assets are also negative, standing at -30.2% and -18.6%, respectively. Day One Biopharmaceuticals has a relatively low debt-to-equity ratio of 0.64 and significant cash reserves of $451.58 million. The valuation context for Day One Biopharmaceuticals shows a forward P/E ratio of -13.19, indicating that the company's stock price is currently lower than its earnings per share. The revenue growth rate has declined by 57.6% year-over-year, while there is no data available on earnings growth. As the dividend yield and payout ratio are not applicable to this company, it does not provide any information on dividend payments.